Get the Stockscreener App
15.09
1.28%
0.19
Ultragenyx Pharmaceutical Inc stock is traded at $15.09, with a volume of 1.47M.
It is up +1.28% in the last 24 hours and up +15.46% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
See More
Previous Close:
$14.90
Open:
$14.87
24h Volume:
1.47M
Relative Volume:
0.37
Market Cap:
$1.49B
Revenue:
$669.43M
Net Income/Loss:
$-609.36M
P/E Ratio:
-2.4713
EPS:
-6.1061
Net Cash Flow:
$-507.20M
1W Performance:
-1.31%
1M Performance:
+15.46%
6M Performance:
-40.07%
1Y Performance:
-54.86%
1-Day Range:
$14.79
$15.27
1-Week Range:
$14.67
$15.73
52-Week Range:
$12.73
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
15.09 | 1.49B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-26 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-03-26 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-03-26 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-03-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-03-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-03-26 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-24-26 | Downgrade | Goldman | Buy → Neutral |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Jul-28-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | William Blair | Outperform |
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Can RARE's Approved Product Portfolio Drive Its Next Growth Phase? - Zacks Investment Research
Funds from operations of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verastem (VSTM), Ultragenyx Pharmaceutical (RARE) and UnitedHealth (UNH) - The Globe and Mail
Ultragenyx Sells Rare Pediatric Disease Priority Review Voucher | PharmExec - Pharmaceutical Executive
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - Pharmaceutical Executive
Ultragenyx cashes in Genglycos-derived priority review voucher for $210M - FirstWord Pharma
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Zacks Investment Research
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash - Yahoo Finance
Ultragenyx to sell rare PRV for $210 million - The Pharma Letter
Is Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy? - Yahoo Finance
Form PRE 14A Ultragenyx Pharmaceutical Inc For: 7 October By Investing.com - Investing.com Nigeria
Ultragenyx Pharmaceutical agrees to sell rare pediatric voucher for US$210M - Mugglehead Investment Magazine
Ultragenyx sells PRV for $210M and still has another voucher it plans to monetize - Endpoints News
Ultragenyx shares rise 3.2% after selling FDA p... - Pluang
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Jumps 3.9%Here's Why - MarketBeat
Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher – Retail Sees ‘Huge’ Buying Opportunity - TradingView
Ultragenyx (RARE) Stock Rises on $210M Priority Review Voucher S - GuruFocus
Ultragenyx to sell FDA priority review voucher for $210M (RARE) - Seeking Alpha
Ultragenyx to sell rare disease priority review voucher for $210m - Investing.com
Ultragenyx (RARE) Sells Rare Pediatric Disease Priority Review V - GuruFocus
Ultragenyx PharmaceuticalUnder Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih - TradingView
Ultragenyx to Sell Priority Review Voucher for $210 Million; 20% Payable to NIH - TradingView
A voucher that can speed FDA review is set to sell for $210 million. - Stock Titan
Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - GlobeNewswire
Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million - Proactive financial news
Ultragenyx (RARE) EMA Validation of MPS IIIA Gene Therapy: Inflection Point or Incremental Milestone? - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of OSI Systems, Inc.OSIS - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Inc. (RARE) stock price, news, quote and history - Yahoo Finance UK
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 6%Here's Why - MarketBeat
Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation - Yahoo Finance
Ultragenyx Pharmaceutical Inc. (RARE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ultragenyx says EMA validates MPS IIIA application - Mugglehead Investment Magazine
Ultragenyx Announces Marketing Authorisation Application - GlobeNewswire
Ultragenyx Pharmaceutical Inc. (RARE.MX) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Ultragenyx Pharmaceutical Inc. (RARE) Options Chain - Yahoo! Finance Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Operating margin % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.8%Time to Buy? - MarketBeat
Cash flow from operating activities of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Return on invested capital % of Ultragenyx Pharmaceutical, Inc. – HAN:UP0 - TradingView
Milestone Sanfilippo nod helps Ultragenyx regroup after tough Angelman defeat - BioSpace
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Has Consensus Price Target of $34.58 According to Analysts - MarketBeat
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com
H.C. Wainwright reiterates Ultragenyx stock rating on FDA approval - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
A Hedge Fund Rolls the Dice on Ultragenyx - Law Street Media
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Ultragenyx Pharmaceutical Inc Stock (RARE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| THEODORE HUIZENGA | Officer |
Sep 15 '26 |
Proposed Sale |
13.61 |
1,283 |
17,462 |
0 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Sep 03 '26 |
Sale |
13.99 |
161 |
2,252 |
69,146 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Aug 03 '26 |
Sale |
24.92 |
1,900 |
47,348 |
92,562 |
| Horn Howard | Chief Financial Officer |
Aug 03 '26 |
Sale |
24.92 |
4,696 |
117,024 |
96,295 |
| HOWARD HORN | Officer |
Aug 03 '26 |
Proposed Sale |
24.92 |
4,696 |
117,024 |
0 |
| Horn Howard | Chief Financial Officer |
Jul 01 '26 |
Sale |
33.13 |
4,698 |
155,645 |
100,991 |
| HOWARD HORN | Officer |
Jul 01 '26 |
Proposed Sale |
33.13 |
4,698 |
155,645 |
0 |
| Sanders Corazon (Corsee) D. | Director |
Jun 15 '26 |
Sale |
25.05 |
2,000 |
50,100 |
21,095 |
| Parschauer Karah Herdman | EVP and Chief Legal Officer |
Jun 15 '26 |
Sale |
24.62 |
1,899 |
46,753 |
94,462 |
| KARAH PARSCHAUER | Officer |
Jun 15 '26 |
Proposed Sale |
24.35 |
3,799 |
92,506 |
0 |
6.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):